02:11:48 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-08-29 Kvartalsrapport 2024-Q2
2024-06-06 Ordinarie utdelning CRNA 0.00 NOK
2024-06-05 Årsstämma 2024
2024-04-25 Bokslutskommuniké 2023
2023-10-04 Split CRNA 30:1
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-22 Årsstämma 2023
2023-04-21 Ordinarie utdelning CRNA 0.00 NOK
2023-03-09 Extra Bolagsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-20 Årsstämma 2022
2022-04-07 Ordinarie utdelning CRNA 0.00 NOK
2022-02-17 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning CRNA 0.00 NOK
2021-03-17 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-30 Ordinarie utdelning CRNA 0.00 NOK
2020-04-29 Årsstämma 2020
2020-03-11 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-04-10 Ordinarie utdelning CRNA 0.00 NOK
2019-04-09 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-12 Ordinarie utdelning CRNA 0.00 NOK
2018-04-11 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-05 Årsstämma 2017
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-14 Ordinarie utdelning CRNA 0.00 NOK
2016-04-13 Årsstämma 2016
2015-06-23 Ordinarie utdelning CRNA 0.00 NOK
2015-06-22 Årsstämma 2015


ListaOB Match
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.
2022-05-10 08:11:53
· Targovax has entered into an agreement with Oslo University Hospital (OUS) to
test TG01 in a phase 1/2 trial in 20 patients with RAS mutant multiple myeloma
· The trial will be sponsored by OUS and led by Dr. Fredrik Schjesvold, an
international leader in the field and founder of the Oslo Myeloma Center, the
largest Myeloma center in the Nordics
· The trial will be the first time TG vaccination is tested in patients
together with the new adjuvant QS-21 STIMULONT from collaboration partner Agenus

Oslo, Norway, 10 May 2022 - Targovax ASA (OSE: TRVX), a clinical-stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that it has entered into a clinical trial collaboration
agreement with Oslo University Hospital (OUS) to run a phase 1/2 study testing
polyvalent mutant RAS vaccine TG01 in multiple myeloma (MM) following standard
of care (SoC) therapy.

Oncogenic mutations in the RAS family of genes drive up to 30% of all cancers
and remain a major unmet medical need with few good treatment alternatives.
Targovax was recently awarded two prestigious research grants from Innovation
Norway and the Norwegian Research Council, totaling NOK 18m, to advance its TG
mutant RAS cancer vaccine program. These grants include funding towards several
clinical studies, of which the first to open will be a TG01 phase 1/2 trial in
MM patients with relevant KRAS and NRAS mutations (approx. 15-20% of MM
patients) to be run in Oslo, Norway.

The trial is a collaboration between OUS and Targovax and will test TG01
vaccination as a monotherapy in 20 KRAS or NRAS mutated MM patients who continue
to have measurable disease after completion of SoC treatment. The aim is to
assess whether anti-RAS T-cell priming induced by TG01 can enhance the clinical
response. OUS will sponsor and be responsible for running and funding the trial,
with Dr. Schjesvold as the principal investigator. Targovax will provide TG01
drug supply, scientific support and financial contribution.

Dr. Fredrik Schjesvold, Founder and Leader Oslo Myeloma Center, at Oslo
University Hospital, and President of the Nordic Myeloma Study Group, said: "RAS
-mutant multiple myeloma has poor prognosis and there are currently no available
targeted treatment options for this patient population. Prior data clearly
demonstrates the capability of TG01 to induce robust anti-RAS T-cell responses
and eliminate residual disease in cancer patients, and suggest that TG
vaccination could be a valuable tool to deepen and prolong responses in multiple
myeloma. Being a Norwegian product makes it particularly interesting, and we
very much look forward to collaborating with Targovax to test this concept in
practice at our center."

Earlier in 2022, Targovax announced a collaboration with Agenus to utilize their
proprietary vaccine adjuvant QS-21 STIMULONT as an immune-stimulatory component
of the TG vaccines for future development and commercialization. QS-21 has
consistently demonstrated powerful antibody and cell-mediated immune responses
both in cancer trials and commercially as a component of the Shingrix[®] and
MosquirixT vaccines. QS-21 should further potentiate the TG vaccines by driving
stronger anti-RAS T-cell responses. The OUS trial will be the first study in
patients of TG01 adjuvanted by QS-21.

Dr. Erik Digman Wiklund, Chief Executive Officer of Targovax ASA, added:
"Following promising data from the first generation TG01 vaccine in pancreatic
cancer, we have focused on enhancing our mutant RAS platform and establishing a
cost-efficient, collaborative development plan to bring the program forward. We
are now ready to bring TG01 back into the clinic in a new and improved format
and are excited to work with Dr. Schjesvold and his team to assess the potential
of TG01 in multiple myeloma. This trial will be the first step in a broader
exploratory program with multiple collaboration partners aimed at testing TG01
vaccination in various RAS mutant cancer types and treatment combinations."


For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.